Mitochondrial genome changes and neurodegenerative diseases

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1842, Issue 8, 2014, Pages 1198-1207

  Pinto, Milena ^a   Moraes, Carlos T ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Encephalopathy; Mitochondrion; MtDNA

Indexed keywords

ASPARAGINE TRANSFER RNA; CYTOCHROME C OXIDASE; GLUTAMIC ACID TRANSFER RNA; GLUTAMINE TRANSFER RNA; GLYCINE TRANSFER RNA; HISTIDINE TRANSFER RNA; ISOLEUCINE TRANSFER RNA; LEUCINE TRANSFER RNA; LYSINE TRANSFER RNA; MITOCHONDRIAL DNA; PHENYLALANINE TRANSFER RNA; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); RNA 16S; SERINE TRANSFER RNA; TRYPTOPHAN TRANSFER RNA; VALINE TRANSFER RNA;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANXIETY DISORDER; ATAXIA; CELL CYCLE; CHOREA; CHRONIC PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA; DEGENERATIVE DISEASE; DEMENTIA; DEPRESSION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DOPAMINERGIC NERVE CELL; DYSTONIA; EXTRACHROMOSOMAL INHERITANCE; FATIGUE; GENE DELETION; HETEROPLASMY; HIPPOCAMPAL CA2 REGION; HOMOPLASMY; HUMAN; INHERITANCE; LEBER HEREDITARY OPTIC NEUROPATHY; LEIGH DISEASE; MELAS SYNDROME; MERRF SYNDROME; MIGRAINE; MITOCHONDRIAL DNA REPLICATION; MITOCHONDRIAL ENCEPHALOPATHY; MITOCHONDRIAL GENOME; MITOCHONDRIAL RESPIRATION; MNGIE SYNDROME; MULTIPLE SCLEROSIS; NONHUMAN; PARKINSON DISEASE; PATHOPHYSIOLOGY; PEARSON SYNDROME; PERCEPTION DEAFNESS; POINT MUTATION; PRIORITY JOURNAL; RETT SYNDROME; REVIEW; SIDEROBLASTIC ANEMIA; SLEEP DISORDER; DNA STRUCTURE; GENE MUTATION; NERVE DEGENERATION;

ENCEPHALOPATHY; MITOCHONDRION; MTDNA;

ANIMALS; DISEASE MODELS, ANIMAL; DNA, MITOCHONDRIAL; GENOME, MITOCHONDRIAL; HUMANS; MITOCHONDRIAL DISEASES; NEURODEGENERATIVE DISEASES; NEURONS;

EID: 84903267268     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2013.11.012     Document Type: Review

References (141)

1. Nass M.M., Nass S. Intramitochondrial fibers with DNA characteristics. I. Fixation and electron staining reactions. J. Cell Biol. 1963, 19:593-611.
2. Anderson S., et al. Sequence and organization of the human mitochondrial genome. Nature 1981, 290(5806):457-465.
3. Chinnery P.F., Hudson G. Mitochondrial genetics. Br. Med. Bull. 2013, 106:135-159.
4. Copeland W.C. Defects in mitochondrial DNA replication and human disease. Crit. Rev. Biochem. Mol. Biol. 2012, 47(1):64-74.
5. Jeppesen D.K., Bohr V.A., Stevnsner T. DNA repair deficiency in neurodegeneration. Prog. Neurobiol. 2011, 94(2):166-200.
6. Kazak L., Reyes A., Holt I.J. Minimizing the damage: repair pathways keep mitochondrial DNA intact. Nat. Rev. Mol. Cell Biol. 2012, 13(10):659-671.
7. Holt I.J., Harding A.E., Morgan-Hughes J.A. Deletions of muscle mitochondrial DNA in patients with mitochondrial myopathies. Nature 1988, 331(6158):717-719.
8. Wallace D.C., et al. Mitochondrial DNA mutation associated with Leber's hereditary optic neuropathy. Science 1988, 242(4884):1427-1430.
9. Elliott H.R., et al. Pathogenic mitochondrial DNA mutations are common in the general population. Am. J. Hum. Genet. 2008, 83(2):254-260.
10. Kelly R.D., et al. Mitochondrial DNA copy number is regulated in a tissue specific manner by DNA methylation of the nuclear-encoded DNA polymerase gamma A. Nucleic Acids Res. 2012, 40(20):10124-10138.
11. Chinnery P.F., et al. Molecular pathology of MELAS and MERRF. The relationship between mutation load and clinical phenotypes. Brain 1997, 120(Pt 10):1713-1721.
12. White S.L., et al. Genetic counseling and prenatal diagnosis for the mitochondrial DNA mutations at nucleotide 8993. Am. J. Hum. Genet. 1999, 65(2):474-482.
13. Rossignol R., et al. Mitochondrial threshold effects. Biochem. J. 2003, 370(Pt 3):751-762.
14. Rahman S., et al. Decrease of 3243 A->G mtDNA mutation from blood in MELAS syndrome: a longitudinal study. Am. J. Hum. Genet. 2001, 68(1):238-240.
15. Weber K., et al. A new mtDNA mutation showing accumulation with time and restriction to skeletal muscle. Am. J. Hum. Genet. 1997, 60(2):373-380.
16. Chinnery P.F., et al. Epigenetics, epidemiology and mitochondrial DNA diseases. Int. J. Epidemiol. 2012, 41(1):177-187.
17. Krishnan K.J., et al. What causes mitochondrial DNA deletions in human cells?. Nat. Genet. 2008, 40(3):275-279.
18. Chen T., et al. The generation of mitochondrial DNA large-scale deletions in human cells. J. Hum. Genet. 2011, 56(10):689-694.
19. Cortopassi G.A., et al. A pattern of accumulation of a somatic deletion of mitochondrial DNA in aging human tissues. Proc. Natl. Acad. Sci. U. S. A. 1992, 89(16):7370-7374.
20. Diaz F., et al. Human mitochondrial DNA with large deletions repopulates organelles faster than full-length genomes under relaxed copy number control. Nucleic Acids Res. 2002, 30(21):4626-4633.
21. Schon E.A., Manfredi G. Neuronal degeneration and mitochondrial dysfunction. J. Clin. Invest. 2003, 111(3):303-312.
22. Lee H.F., et al. The neurological evolution of Pearson syndrome: case report and literature review. Eur. J. Paediatr. Neurol. 2007, 11(4):208-214.
23. McShane M.A., et al. Pearson syndrome and mitochondrial encephalomyopathy in a patient with a deletion of mtDNA. Am. J. Hum. Genet. 1991, 48(1):39-42.
24. Manea E.M., et al. Pearson syndrome in the neonatal period: two case reports and review of the literature. J. Pediatr. Hematol. Oncol. 2009, 31(12):947-951.
25. Aure K., et al. Chronic progressive ophthalmoplegia with large-scale mtDNA rearrangement: can we predict progression?. Brain 2007, 130(Pt 6):1516-1524.
26. Moraes C.T., et al. Mitochondrial DNA deletions in progressive external ophthalmoplegia and Kearns-Sayre syndrome. N. Engl. J. Med. 1989, 320(20):1293-1299.
27. Spector R., Johanson C.E. Choroid plexus failure in the Kearns-Sayre syndrome. Cerebrospinal Fluid Res. 2010, 7:14.
28. Koilkonda R.D., Guy J. Leber's hereditary optic neuropathy-gene therapy: from benchtop to bedside. J. Ophthalmol. 2011, 2011:179412.
29. Carelli V., et al. Bioenergetics shapes cellular death pathways in Leber's hereditary optic neuropathy: a model of mitochondrial neurodegeneration. Biochim. Biophys. Acta 2004, 1658(1-2):172-179.
30. Beretta S., et al. Leber hereditary optic neuropathy mtDNA mutations disrupt glutamate transport in cybrid cell lines. Brain 2004, 127(Pt 10):2183-2192.
31. Spruijt L., et al. Influence of mutation type on clinical expression of Leber hereditary optic neuropathy. Am J. Ophthalmol. 2006, 141(4):676-682.
32. Marin S.E., et al. Leigh syndrome associated with mitochondrial complex I deficiency due to novel mutations in NDUFV1 and NDUFS2. Gene 2013, 516(1):162-167.
33. Martin M.A., et al. Leigh syndrome associated with mitochondrial complex I deficiency due to a novel mutation in the NDUFS1 gene. Arch. Neurol. 2005, 62(4):659-661.
34. Sarzi E., et al. A novel recurrent mitochondrial DNA mutation in ND3 gene is associated with isolated complex I deficiency causing Leigh syndrome and dystonia. Am. J. Med. Genet. A 2007, 143(1):33-41.
35. Thorburn D.R., Rahman S. Mitochondrial DNA-associated Leigh syndrome and NARP. GeneReviews 1993, (Seattle (WA)). R.A. Pagon (Ed.).
36. Kirby D.M., et al. Low mutant load of mitochondrial DNA G13513A mutation can cause Leigh's disease. Ann. Neurol. 2003, 54(4):473-478.
37. Santorelli F.M., et al. Heterogeneous clinical presentation of the mtDNA NARP/T8993G mutation. Neurology 1997, 49(1):270-273.
38. Leshinsky-Silver E., et al. Neonatal liver failure and Leigh syndrome possibly due to CoQ-responsive OXPHOS deficiency. Mol. Genet. Metab. 2003, 79(4):288-293.
39. Debrosse S., Parikh S. Neurologic disorders due to mitochondrial DNA mutations. Semin. Pediatr. Neurol. 2012, 19(4):194-202.
40. Tanji K., et al. Neuropathological features of mitochondrial disorders. Semin. Cell Dev. Biol. 2001, 12(6):429-439.
41. Donovan L.E., Severin N.E. Maternally inherited diabetes and deafness in a North American kindred: tips for making the diagnosis and review of unique management issues. J. Clin. Endocrinol. Metab. 2006, 91(12):4737-4742.
42. Laloi-Michelin M., et al. The clinical variability of maternally inherited diabetes and deafness is associated with the degree of heteroplasmy in blood leukocytes. J. Clin. Endocrinol. Metab. 2009, 94(8):3025-3030.
43. Olmos P.R., et al. Mitochondrial diabetes and deafness: possible dysfunction of strial marginal cells of the inner ear. J. Otolaryngol. Head Neck Surg. 2011, 40(2):93-103.
44. Shoffner J.M., et al. Myoclonic epilepsy and ragged-red fiber disease (MERRF) is associated with a mitochondrial DNA tRNA(Lys) mutation. Cell 1990, 61(6):931-937.
45. Larsson N.G., et al. Pathogenetic aspects of the A8344G mutation of mitochondrial DNA associated with MERRF syndrome and multiple symmetric lipomas. Muscle Nerve Suppl. 1995, 3:S102-S106.
46. Sparaco M., et al. Neuropathology of mitochondrial encephalomyopathies due to mitochondrial DNA defects. J. Neuropathol. Exp. Neurol. 1993, 52(1):1-10.
47. Fukuhara N. MERRF: a clinicopathological study. Relationships between myoclonus epilepsies and mitochondrial myopathies. Rev. Neurol. (Paris) 1991, 147(6-7):476-479.
48. Zhou L., et al. Myoclonic epilepsy and ragged red fibers (MERRF) syndrome: selective vulnerability of CNS neurons does not correlate with the level of mitochondrial tRNAlys mutation in individual neuronal isolates. J. Neurosci. 1997, 17(20):7746-7753.
49. Prezant T.R., et al. Mitochondrial ribosomal RNA mutation associated with both antibiotic-induced and non-syndromic deafness. Nat. Genet. 1993, 4(3):289-294.
50. Duno M., et al. A novel mitochondrial mutation m.8989G>C associated with neuropathy, ataxia, retinitis pigmentosa - the NARP syndrome. Gene 2013, 515(2):372-375.
51. Milenkovic D., et al. TWINKLE is an essential mitochondrial helicase required for synthesis of nascent D-loop strands and complete mtDNA replication. Hum. Mol. Genet. 2013, 22(10):1983-1993.
52. Spelbrink J.N., et al. Human mitochondrial DNA deletions associated with mutations in the gene encoding Twinkle, a phage T7 gene 4-like protein localized in mitochondria. Nat. Genet. 2001, 28(3):223-231.
53. Stumpf J.D., Saneto R.P., Copeland W.C. Clinical and molecular features of POLG-related mitochondrial disease. Cold Spring Harb. Perspect. Biol. 2013, 5(4):a011395.
54. Lamantea E., et al. Mutations of mitochondrial DNA polymerase gammaA are a frequent cause of autosomal dominant or recessive progressive external ophthalmoplegia. Ann. Neurol. 2002, 52(2):211-219.
55. Fratter C., et al. The clinical, histochemical, and molecular spectrum of PEO1 (Twinkle)-linked adPEO. Neurology 2010, 74(20):1619-1626.
56. Brandon B.R., et al. Autosomal dominant mutations in POLG and C10orf2: association with late onset chronic progressive external ophthalmoplegia and Parkinsonism in two patients. J. Neurol. 2013, 260(7):1931-1933.
57. Reeve A., et al. The impact of pathogenic mitochondrial DNA mutations on substantia nigra neurons. J. Neurosci. 2013, 33(26):10790-10801.
58. Tzoulis C., et al. Severe nigrostriatal degeneration without clinical parkinsonism in patients with polymerase gamma mutations. Brain 2013, 136(Pt 8):2393-2404.
59. Nishino I., Spinazzola A., Hirano M. Thymidine phosphorylase gene mutations in MNGIE, a human mitochondrial disorder. Science 1999, 283(5402):689-692.
60. Suh B.C., et al. Compound heterozygous mutations of TYMP as underlying causes of mitochondrial neurogastrointestinal encephalomyopathy (MNGIE). Mol. Med. Rep. 2013, 8(1):17-22.
61. Hudson G., et al. Mutation of OPA1 causes dominant optic atrophy with external ophthalmoplegia, ataxia, deafness and multiple mitochondrial DNA deletions: a novel disorder of mtDNA maintenance. Brain 2008, 131(Pt 2):329-337.
62. Amati-Bonneau P., et al. OPA1 mutations induce mitochondrial DNA instability and optic atrophy 'plus' phenotypes. Brain 2008, 131(Pt 2):338-351.
63. Tyynismaa H., et al. A heterozygous truncating mutation in RRM2B causes autosomal-dominant progressive external ophthalmoplegia with multiple mtDNA deletions. Am. J. Hum. Genet. 2009, 85(2):290-295.
64. Bourdon A., et al. Mutation of RRM2B, encoding p53-controlled ribonucleotide reductase (p53R2), causes severe mitochondrial DNA depletion. Nat. Genet. 2007, 39(6):776-780.
65. Clay Montier L.L., Deng J.J., Bai Y. Number matters: control of mammalian mitochondrial DNA copy number. J. Genet. Genomics 2009, 36(3):125-131.
66. Uusimaa J., et al. Clinical, biochemical, cellular and molecular characterization of mitochondrial DNA depletion syndrome due to novel mutations in the MPV17 gene. Eur. J. Hum. Genet. 2013, [in press].
67. Sarzi E., et al. Twinkle helicase (PEO1) gene mutation causes mitochondrial DNA depletion. Ann. Neurol. 2007, 62(6):579-587.
68. Lv H., et al. Mitofusin 2 gene mutation causing early-onset CMT2A with different progressive courses. Clin. Neuropathol. 2013, 32(1):16-23.
69. El-Hattab A.W., Scaglia F. Mitochondrial DNA depletion syndromes: review and updates of genetic basis, manifestations, and therapeutic options. Neurotherapeutics 2013, 10(2):186-198.
70. Miller C., et al. The interplay between SUCLA2, SUCLG2, and mitochondrial DNA depletion. Biochim. Biophys. Acta 2011, 1812(5):625-629.
71. Spinazzola A., Zeviani M. Disorders of nuclear-mitochondrial intergenomic communication. Biosci. Rep. 2007, 27(1-3):39-51.
72. Exner N., et al. Mitochondrial dysfunction in Parkinson's disease: molecular mechanisms and pathophysiological consequences. EMBO J. 2012, 31(14):3038-3062.
73. Xie W., Wan O.W., Chung K.K. New insights into the role of mitochondrial dysfunction and protein aggregation in Parkinson's disease. Biochim. Biophys. Acta 2010, 1802(11):935-941.
74. Lin M.T., Beal M.F. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 2006, 443(7113):787-795.
75. Fukae J., Mizuno Y., Hattori N. Mitochondrial dysfunction in Parkinson's disease. Mitochondrion 2007, 7(1-2):58-62.
76. Braak H., et al. Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson's disease (preclinical and clinical stages). J. Neurol. 2002, 249(Suppl. 3). (p. III/1-5).
77. Pinto M., Pickrell A.M., Moraes C.T. Regional susceptibilities to mitochondrial dysfunctions in the CNS. Biol. Chem. 2012, 393(4):275-281.
78. Bender A., et al. High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease. Nat. Genet. 2006, 38(5):515-517.
79. Kraytsberg Y., et al. Mitochondrial DNA deletions are abundant and cause functional impairment in aged human substantia nigra neurons. Nat. Genet. 2006, 38(5):518-520.
80. Ekstrand M.I., Galter D. The MitoPark Mouse - an animal model of Parkinson's disease with impaired respiratory chain function in dopamine neurons. Parkinsonism Relat. Disord. 2009, 15(Suppl. 3):S185-S188.
81. Pickrell A.M., et al. Striatal dysfunctions associated with mitochondrial DNA damage in dopaminergic neurons in a mouse model of Parkinson's disease. J. Neurosci. 2011, 31(48):17649-17658.
82. Song L., et al. Mutant Twinkle increases dopaminergic neurodegeneration, mtDNA deletions and modulates Parkin expression. Hum. Mol. Genet. 2012, 21(23):5147-5158.
83. Palin E.J., Paetau A., Suomalainen A. Mesencephalic complex I deficiency does not correlate with parkinsonism in mitochondrial DNA maintenance disorders. Brain 2013, 136(Pt 8):2379-2392.
84. Hudson G., et al. Two-stage association study and meta-analysis of mitochondrial DNA variants in Parkinson disease. Neurology 2013, 80(22):2042-2048.
85. Long J., et al. New evidence of mitochondria dysfunction in the female Alzheimer's disease brain: deficiency of estrogen receptor-beta. J. Alzheimers Dis. 2012, 30(3):545-558.
86. Sheng B., et al. Impaired mitochondrial biogenesis contributes to mitochondrial dysfunction in Alzheimer's disease. J. Neurochem. 2012, 120(3):419-429.
87. Calkins M.J., et al. Impaired mitochondrial biogenesis, defective axonal transport of mitochondria, abnormal mitochondrial dynamics and synaptic degeneration in a mouse model of Alzheimer's disease. Hum. Mol. Genet. 2011, 20(23):4515-4529.
88. Chen J.X., Yan S.S. Role of mitochondrial amyloid-beta in Alzheimer's disease. J. Alzheimers Dis. 2010, 20(Suppl. 2):S569-S578.
89. Fukui H., et al. Cytochrome c oxidase deficiency in neurons decreases both oxidative stress and amyloid formation in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 2007, 104(35):14163-14168.
90. Pinto M., et al. Mitochondrial DNA damage in a mouse model of Alzheimer's disease decreases amyloid beta plaque formation. Neurobiol. Aging 2013, 34(10):2399-2407.
91. Area-Gomez E., et al. Upregulated function of mitochondria-associated ER membranes in Alzheimer disease. EMBO J. 2012, 31(21):4106-4123.
92. Schon E.A., Area-Gomez E. Is Alzheimer's disease a disorder of mitochondria-associated membranes?. J. Alzheimers Dis. 2010, 20(Suppl. 2):S281-S292.
93. Schon E.A., Area-Gomez E. Mitochondria-associated ER membranes in Alzheimer disease. Mol. Cell. Neurosci. 2013, 55:26-36.
94. Coskun P.E., Beal M.F., Wallace D.C. Alzheimer's brains harbor somatic mtDNA control-region mutations that suppress mitochondrial transcription and replication. Proc. Natl. Acad. Sci. U. S. A. 2004, 101(29):10726-10731.
95. Krishnan K.J., et al. Mitochondrial DNA deletions cause the biochemical defect observed in Alzheimer's disease. Neurobiol. Aging 2012, 33(9):2210-2214.
96. Lin M.T., et al. High aggregate burden of somatic mtDNA point mutations in aging and Alzheimer's disease brain. Hum. Mol. Genet. 2002, 11(2):133-145.
97. Elson J.L., et al. Does the mitochondrial genome play a role in the etiology of Alzheimer's disease?. Hum. Genet. 2006, 119(3):241-254.
98. Tanaka N., et al. Mitochondrial DNA variants in a Japanese population of patients with Alzheimer's disease. Mitochondrion 2010, 10(1):32-37.
99. Mancuso M., et al. Mitochondrial DNA sequence variation and neurodegeneration. Hum. Genomics 2008, 3(1):71-78.
100. Dhaliwal G.K., Grewal R.P. Mitochondrial DNA deletion mutation levels are elevated in ALS brains. Neuroreport 2000, 11(11):2507-2509.
101. Ro L.S., et al. Deleted 4977-bp mitochondrial DNA mutation is associated with sporadic amyotrophic lateral sclerosis: a hospital-based case-control study. Muscle Nerve 2003, 28(6):737-743.
102. Keeney P.M., Bennett J.P. ALS spinal neurons show varied and reduced mtDNA gene copy numbers and increased mtDNA gene deletions. Mol. Neurodegener. 2010, 5:21.
103. Comi G.P., et al. Cytochrome c oxidase subunit I microdeletion in a patient with motor neuron disease. Ann. Neurol. 1998, 43(1):110-116.
104. Kirches E., et al. Mitochondrial tRNA(Cys) mutation A5823G in a patient with motor neuron disease and temporal lobe epilepsy. Pathobiology 1999, 67(4):214-218.
105. Zhao D., et al. Chronic progressive external ophthalmoplegia coexistent with motor neuron disease in a patient with a novel large-scale mitochondrial DNA deletion. Clin. Neurol. Neurosurg. 2012, 115(8):1490-1492.
106. Borthwick G.M., et al. Motor neuron disease in a patient with a mitochondrial tRNAIle mutation. Ann. Neurol. 2006, 59(3):570-574.
107. Ingram C.J., et al. Analysis of European case-control studies suggests that common inherited variation in mitochondrial DNA is not involved in susceptibility to amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. 2012, 13(4):341-346.
108. Witte M.E., et al. Reduced expression of PGC-1alpha partly underlies mitochondrial changes and correlates with neuronal loss in multiple sclerosis cortex. Acta Neuropathol. 2013, 125(2):231-243.
109. Pandit A., et al. Impaired regulation of electron transport chain subunit genes by nuclear respiratory factor 2 in multiple sclerosis. J. Neurol. Sci. 2009, 279(1-2):14-20.
110. Dutta R., et al. Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients. Ann. Neurol. 2006, 59(3):478-489.
111. Andalib S., et al. Multiple sclerosis and mitochondrial gene variations: a review. J. Neurol. Sci. 2013, 330(1-2):10-15.
112. Campbell G.R., et al. Mitochondrial DNA deletions and depletion within paraspinal muscles. Neuropathol. Appl. Neurobiol. 2013, 39(4):377-389.
113. Fan W., et al. A mouse model of mitochondrial disease reveals germline selection against severe mtDNA mutations. Science 2008, 319(5865):958-962.
114. Wallace D.C., Fan W. The pathophysiology of mitochondrial disease as modeled in the mouse. Genes Dev. 2009, 23(15):1714-1736.
115. McKenzie M., et al. Production of homoplasmic xenomitochondrial mice. Proc. Natl. Acad. Sci. U. S. A. 2004, 101(6):1685-1690.
116. Tyynismaa H., Suomalainen A. Mouse models of mitochondrial DNA defects and their relevance for human disease. EMBO Rep. 2009, 10(2):137-143.
117. Larsson N.G., et al. Mitochondrial transcription factor A is necessary for mtDNA maintenance and embryogenesis in mice. Nat. Genet. 1998, 18(3):231-236.
118. Sorensen L., et al. Late-onset corticohippocampal neurodepletion attributable to catastrophic failure of oxidative phosphorylation in MILON mice. J. Neurosci. 2001, 21(20):8082-8090.
119. Ekstrand M.I., et al. Progressive parkinsonism in mice with respiratory-chain-deficient dopamine neurons. Proc. Natl. Acad. Sci. U. S. A. 2007, 104(4):1325-1330.
120. Hance N., Ekstrand M.I., Trifunovic A. Mitochondrial DNA polymerase gamma is essential for mammalian embryogenesis. Hum. Mol. Genet. 2005, 14(13):1775-1783.
121. Trifunovic A., et al. Premature ageing in mice expressing defective mitochondrial DNA polymerase. Nature 2004, 429(6990):417-423.
122. Kujoth G.C., et al. Mitochondrial DNA mutations, oxidative stress, and apoptosis in mammalian aging. Science 2005, 309(5733):481-484.
123. Williams S.L., et al. The mtDNA mutation spectrum of the progeroid Polg mutator mouse includes abundant control region multimers. Cell Metab. 2010, 12(6):675-682.
124. Dai Y., et al. Behavioral and metabolic characterization of heterozygous and homozygous POLG mutator mice. Mitochondrion 2013, 13(4):282-291.
125. Tyynismaa H., et al. Mutant mitochondrial helicase Twinkle causes multiple mtDNA deletions and a late-onset mitochondrial disease in mice. Proc. Natl. Acad. Sci. U. S. A. 2005, 102(49):17687-17692.
126. Lopez L.C., et al. Unbalanced deoxynucleotide pools cause mitochondrial DNA instability in thymidine phosphorylase-deficient mice. Hum. Mol. Genet. 2009, 18(4):714-722.
127. Spinazzola A., et al. MPV17 encodes an inner mitochondrial membrane protein and is mutated in infantile hepatic mitochondrial DNA depletion. Nat. Genet. 2006, 38(5):570-575.
128. Zhou X., et al. Progressive loss of mitochondrial DNA in thymidine kinase 2-deficient mice. Hum. Mol. Genet. 2008, 17(15):2329-2335.
129. Akman H.O., et al. Thymidine kinase 2 (H126N) knockin mice show the essential role of balanced deoxynucleotide pools for mitochondrial DNA maintenance. Hum. Mol. Genet. 2008, 17(16):2433-2440.
130. Lauritzen K.H., et al. Modeling the impact of mitochondrial DNA damage in forebrain neurons and beyond. Mech. Ageing Dev. 2011, 132(8-9):424-428.
131. Inoue K., et al. Generation of mice with mitochondrial dysfunction by introducing mouse mtDNA carrying a deletion into zygotes. Nat. Genet. 2000, 26(2):176-181.
132. Pinkert C.A., Trounce I.A. Generation of transmitochondrial mice: development of xenomitochondrial mice to model neurodegenerative diseases. Methods Cell Biol. 2007, 80:549-569.
133. Yokota M., et al. Generation of trans-mitochondrial mito-mice by the introduction of a pathogenic G13997A mtDNA from highly metastatic lung carcinoma cells. FEBS Lett. 2010, 584(18):3943-3948.
134. Kasahara A., et al. Generation of trans-mitochondrial mice carrying homoplasmic mtDNAs with a missense mutation in a structural gene using ES cells. Hum. Mol. Genet. 2006, 15(6):871-881.
135. Nakada K., Hayashi J. Transmitochondrial mice as models for mitochondrial DNA-based diseases. Exp. Anim. 2011, 60(5):421-431.
136. Lin C.S., et al. Mouse mtDNA mutant model of Leber hereditary optic neuropathy. Proc. Natl. Acad. Sci. U. S. A. 2012, 109(49):20065-20070.
137. Srivastava S., Moraes C.T. Double-strand breaks of mouse muscle mtDNA promote large deletions similar to multiple mtDNA deletions in humans. Hum. Mol. Genet. 2005, 14(7):893-902.
138. Fukui H., Moraes C.T. Mechanisms of formation and accumulation of mitochondrial DNA deletions in aging neurons. Hum. Mol. Genet. 2009, 18(6):1028-1036.
139. Pickrell A.M., et al. The striatum is highly susceptible to mitochondrial oxidative phosphorylation dysfunctions. J. Neurosci. 2011, 31(27):9895-9904.
140. Pinto M., et al. Mitochondrial DNA damage in a mouse model of Alzheimer's disease decreases amyloid beta plaque formation. Neurobiol. Aging 2013, 34(10):2399-2407.
141. Williams S.L., Mash D.C., Züchner S., Moraes C.T. Somatic mtDNA mutation spectra in the aging human putamen. PLoS Genet. 2013, 9(12):e1003990.